The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Oct 19, 2026
Snapshot (as of Oct 19, 2026): Viatris Inc. (VTRS) pays a $0.48 annual dividend ($0.12 quarterly), yielding 2.57% at $18.66/share. Next ex-dividend date 2026-08-21. 5 consecutive years of dividend growth. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 2.57%
Annual Dividend: $0.48 per share
Payout Ratio: 960.0% (based on depressed trailing earnings — see safety analysis below)
Ex-Dividend Date: 2026-08-21
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 28
Viatris Inc. dividend income comes from a global healthcare company that manufactures and sells prescription brand drugs, generics, and biosimilars across more than a dozen markets worldwide. VTRS carries a current yield of 2.72%, with a trailing annual dividend rate of $0.48 per share paid quarterly. The next ex-dividend date is August 21, 2026. With a beta of 0.858, Viatris Inc. stock moves less than the broader market, which appeals to income investors who prioritize lower price volatility.
Viatris Inc. pays out 960% of earnings as dividends, a payout ratio classified as high (above 75%) — far above it, in fact. The company's portfolio spans cardiovascular, oncology, respiratory, and other therapeutic categories, with products like EpiPen, Lipitor, and Lyrica serving retail pharmacies, wholesalers, and institutions globally, providing broad demand across its revenue base. Viatris Inc. dividend safety is the central concern here: a payout ratio this elevated means the dividend is not covered by reported earnings, and any sustained earnings pressure would put the current $0.48 annual rate at risk.
Viatris Inc. dividend history shows a CAGR of 6.8% per year from 1996 to 2025. Per-share payments grew from $0.0712 to $0.4800 over that period (2026 is a partial year and excluded from the CAGR calculation). The largest annual increase in the window was 100% in 2022, when the dividend jumped sharply. Since 2022, the annual rate has held flat at $0.4800, meaning growth has stalled in the most recent years despite the long-run CAGR looking respectable on paper.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | 0.0% | $0.48 (2022) | $0.48 (2025) |
| 5-Year | +32.0% | $0.12 (2007) | $0.48 (2025) |
| 10-Year | +20.3% | $0.08 (2002) | $0.48 (2025) |
VTRS fits dividend investors who want moderate income from a globally diversified healthcare business and can tolerate a high payout ratio. The current yield of 2.72% falls in the moderate (2-4%) range, sitting below the 5-year average yield of 3.88%, which means the stock is delivering less income relative to its own history. Five consecutive years of dividend increases show a willingness to grow the payout, but the 960% payout ratio is the defining trade-off: income investors get a globally scaled drug manufacturer with recognized brands, but they accept meaningful coverage risk in exchange.
| Payment Date | Amount per Share |
|---|---|
| 2026-08-21 | $0.1200 |
| 2026-05-22 | $0.1200 |
| 2026-03-09 | $0.1200 |
| 2025-11-24 | $0.1200 |
| 2025-08-22 | $0.1200 |
| 2025-05-23 | $0.1200 |
| 2025-03-10 | $0.1200 |
| 2024-11-22 | $0.1200 |
| 2024-08-23 | $0.1200 |
| 2024-05-23 | $0.1200 |
| Year | Total Dividends |
|---|---|
| 2026 | $0.3600 |
| 2025 | $0.4800 |
| 2024 | $0.4800 |
| 2023 | $0.4800 |
| 2022 | $0.4800 |
Project income from VTRS with the VTRS dividend calculator or track your full portfolio with the dividend tracker.